Status:

COMPLETED

Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning Features

Lead Sponsor:

Nanjing Medical University

Collaborating Sponsors:

The Affiliated cancer hospital of Nanjing Medical University

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Conditions:

Esophageal Squamous Cell Carcinoma

Pathological Complete Response

Eligibility:

All Genders

18+ years

Brief Summary

This multicenter, retrospective cohort study reviews the medical records and CT scans of adults with esophageal squamous cell carcinoma (ESCC) who received neoadjuvant immunotherapy plus chemotherapy ...

Detailed Description

Design and Setting. Multicenter, retrospective cohort study conducted at three affiliated hospitals in China. A total of 363 consecutive ESCC patients met eligibility criteria and were split into a tr...

Eligibility Criteria

Inclusion

  • Biopsy-confirmed esophageal squamous cell carcinoma (ESCC). Locally advanced disease per AJCC 8th ed. (cT1N1-T3N0-3M0) on contrast-enhanced CT.
  • Completed standardized neoadjuvant chemo-immunotherapy (e.g., paclitaxel + cisplatin/carboplatin with camrelizumab every 2-3 weeks) prior to surgery.
  • High-quality venous-phase chest CT (slice thickness ≤5 mm) obtained within 14 days before therapy start.
  • Underwent R0 resection 6-8 weeks after therapy. Availability of a definitive postoperative pathology report to ascertain pCR status.

Exclusion

  • Non-squamous histology; distant metastasis (M1); synchronous malignancies. Inadequate imaging quality (no venous phase, slice thickness \>5 mm, severe artifacts, or incomplete tumor visualization).
  • Did not complete the full treatment course or had missing endpoints (e.g., no pathological response record or lost to follow-up).

Key Trial Info

Start Date :

January 1 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 31 2025

Estimated Enrollment :

363 Patients enrolled

Trial Details

Trial ID

NCT07181850

Start Date

January 1 2019

End Date

July 31 2025

Last Update

September 18 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University

Huai'an, Jiangsu, China, 223000